Take­da wins long-await­ed US ap­proval for first oral drug for eosinophilic esophagi­tis

The FDA on Mon­day ap­proved Take­da’s Eo­hil­ia, the first oral drug for pa­tients with eosinophilic esophagi­tis (EoE) in the US, which the com­pa­ny briefly aban­doned af­ter re­ceiv­ing a com­plete re­sponse let­ter.

Take­da will now have to com­pete with Sanofi and Re­gen­eron’s block­buster Dupix­ent, which won its ex­pand­ed ap­proval in EoE in 2022. EoE caus­es in­flam­ma­tion of the esoph­a­gus, lead­ing to vom­it­ing, dif­fi­cul­ty swal­low­ing and pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER